BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu P, Gao C, Chen H, Vong CT, Wu X, Tang X, Wang S, Wang Y. Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. Acta Pharm Sin B 2021;11:2798-818. [PMID: 34589398 DOI: 10.1016/j.apsb.2020.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Nakkala JR, Li Z, Ahmad W, Wang K, Gao C. Immunomodulatory biomaterials and their application in therapies for chronic inflammation-related diseases. Acta Biomater 2021;123:1-30. [PMID: 33484912 DOI: 10.1016/j.actbio.2021.01.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
2 Liu C, Yan X, Zhang Y, Yang M, Ma Y, Zhang Y, Xu Q, Tu K, Zhang M. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. J Nanobiotechnology 2022;20:206. [PMID: 35488343 DOI: 10.1186/s12951-022-01421-w] [Reference Citation Analysis]
3 Sriram A, Tangirala S, Atmakuri S, Hoque S, Modani S, Srivastava S, Mahajan S, Maji I, Kumar R, Khatri D, Madan J, Singh PK. Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech 2021;22:264. [PMID: 34734325 DOI: 10.1208/s12249-021-02133-4] [Reference Citation Analysis]
4 Le Z, He Z, Liu H, Liu L, Liu Z, Chen Y. Antioxidant Enzymes Sequestered within Lipid-Polymer Hybrid Nanoparticles for the Local Treatment of Inflammatory Bowel Disease. ACS Appl Mater Interfaces 2021;13:55966-77. [PMID: 34792322 DOI: 10.1021/acsami.1c19457] [Reference Citation Analysis]
5 Ao H, Wang Z, Lu L, Ma H, Li H, Fu J, Li M, Han M, Guo Y, Wang X. Enhanced tumor accumulation and therapeutic efficacy of liposomal drugs through over-threshold dosing. J Nanobiotechnology 2022;20:137. [PMID: 35292036 DOI: 10.1186/s12951-022-01349-1] [Reference Citation Analysis]
6 Li X, Fang S, Yu Y, Yang H, Rao Y, Hong D, Lu C, Yu M, Lu X, Yu C, Zhao Q. Oral administration of inflammatory microenvironment-responsive carrier-free infliximab nanocomplex for the targeted treatment of inflammatory bowel disease. Chemical Engineering Journal 2022;445:136438. [DOI: 10.1016/j.cej.2022.136438] [Reference Citation Analysis]
7 Zhang C, Li J, Xiao M, Wang D, Qu Y, Zou L, Zheng C, Zhang J. Oral colon-targeted mucoadhesive micelles with enzyme-responsive controlled release of curcumin for ulcerative colitis therapy. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.110] [Reference Citation Analysis]
8 Turanlı Y, Acartürk F. Preparation and characterization of colon-targeted pH/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur J Pharm Sci 2022;171:106122. [PMID: 35007712 DOI: 10.1016/j.ejps.2022.106122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen S, Zhu H, Luo Y. Chitosan-based oral colon-specific delivery systems for polyphenols: recent advances and emerging trends. J Mater Chem B 2022. [PMID: 35766297 DOI: 10.1039/d2tb00874b] [Reference Citation Analysis]
10 Vitulo M, Gnodi E, Meneveri R, Barisani D. Interactions between Nanoparticles and Intestine. IJMS 2022;23:4339. [DOI: 10.3390/ijms23084339] [Reference Citation Analysis]